Home > Boards > US Listed > Biotechs > Seattle Genetics (SGEN)

*****AML Therapies: Seattle Genetics Vs. GlycoMimetics

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 407
Posts 54,289
Boards Moderated 26
Alias Born 12/16/01
160x600 placeholder
Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Comb... Business Wire - 4/2/2020 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/1/2020 4:22:54 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/1/2020 4:19:34 PM
Unknown (sec Staff) Edgar (US Regulatory) - 3/18/2020 2:11:52 PM
Unknown (sec Staff) Edgar (US Regulatory) - 3/18/2020 2:11:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2020 6:52:07 PM
Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference Business Wire - 3/10/2020 8:00:00 AM
Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference Business Wire - 3/2/2020 8:00:00 AM
Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference Business Wire - 2/26/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/20/2020 5:34:37 PM
Five Prime Therapeutics In License Agreement with Seattle Genetics Dow Jones News - 2/19/2020 10:31:00 AM
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combina... PR Newswire (US) - 2/19/2020 8:28:00 AM
Seattle Genetics & Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combinati... Business Wire - 2/19/2020 8:12:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 1:38:19 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 12:11:05 PM
Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients wit... Business Wire - 2/13/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/12/2020 5:39:52 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 2:53:27 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 11:15:05 AM
Seattle Genetics & Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combinat... Business Wire - 2/11/2020 8:00:00 AM
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combin... PR Newswire (US) - 2/10/2020 5:00:00 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/7/2020 8:46:46 AM
Annual Report (10-k) Edgar (US Regulatory) - 2/6/2020 5:19:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/6/2020 4:11:25 PM
Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire - 2/6/2020 4:02:00 PM
TREND1 Member Level  Saturday, 07/16/16 11:28:41 AM
Re: None
Post # of 254 
*****AML Therapies: Seattle Genetics Vs. GlycoMimetics

ALSO JUNO MENTIONED

Jul. 15, 2016 8:10 AM ET
About: GlycoMimetics (GLYC), SGEN, Includes: JUNO


William Meyers
Follow (1,085 followers)

Long only, tech, biotech, research analyst


Summary


•Acute Myeloid Leukemia is very difficult to treat successfully.

•Seattle Genetics SGN-CD33A started a Phase 3 trial.

•GlycoMimetics GMI-1271 started Phase 2 trial.

•There are other competitors, but it is unlikely AML will be 100% cured by any one therapy.



http://seekingalpha.com/article/3988622-aml-therapies-seattle-genetics-vs-glycomimetics?ifp=0&app=1

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist